Miyamoto N, et al. - From July 2009 to June 2011, investigators examined the data to evaluate whether the first-choice treatment, either photodynamic therapy (PDT) or intravitreal ranibizumab, had a long-term influence in subjects with polypoidal choroidal vasculopathy (PCV). They noted that the logarithm of minimal angle of resolution visual acuity (VA) was 0.56 in the PDT and 0.44 in the ranibizumab groups at baseline and was 0.55 and 0.28 at 5 years, respectively. They found the conversion of more than 70% of the subjects to aflibercept in the later years. They recorded achievement percentages of the dry macula, 74% (PDT) and 63% (ranibizumab) at 5 years, and macular atrophy detected in 78% (PDT) and 60% (ranibizumab) with a mean area of 7.7 and 3.5 mm², respectively.